The amyloid hypothesis has been considered a major explanation of the pathogenesis of Alzheimer disease. However, failure of phase III clinical trials with anti-amyloid-beta monoclonal antibodies reveals the need for other therapeutic approaches to treat Alzheimer disease. Compared to its relatively short history, optogenetics has developed considerably. The expression of microbial opsins in cells using genetic engineering allows specific control of cell signals or molecules. The application of optogenetics to Alzheimer disease research or clinical approaches is increasing. When applied with gamma entrainment, optogenetic neuromodulation can improve Alzheimer disease symptoms. Although safety problems exist with optogenetics such as the use of viral vectors, this technique has great potential for use in Alzheimer disease. In this paper, we review the historical applications of optogenetic neuromodulation with gamma entrainment to investigate the mechanisms involved in Alzheimer disease and potential therapeutic strategies.
Citations
Citations to this article as recorded by
Modulating Proteasome Function with Polyphenol Metabolites: A Promising Therapeutic Avenue for Alzheimer's Disease Nyerovwo Charity Okei European Journal of Medical and Health Research.2024; 2(2): 16. CrossRef
Exogenous AMPA downregulates gamma-frequency network oscillation in CA3 of rat hippocampal slices Chengzhang Li, Zhenrong Li, Sihan Xu, Sanwei Jiang, Zhenli Ye, Bin Yu, Shixiang Gong, Junmei Li, Qilin Hu, Bingyan Feng, Mengmeng Wang, Chengbiao Lu Scientific Reports.2023;[Epub] CrossRef
Light-Controlled Modulation and Analysis of Neuronal Functions Carlo Matera, Piotr Bregestovski International Journal of Molecular Sciences.2022; 23(21): 12921. CrossRef